Tiziana Life Sciences Ltd
TLSA · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D49gen composite 16pct→49
Notable findings
- No interest coverageInterest coverage -8.94 (cannot cover interest)
- Cash burnNegative free cash flow (-1.5M)
- Trial readout soonUpcoming trial readout ~2026-04-30 — PHASE2 · Non-Active Secondary Progressive Multiple Sclerosis
Key metrics
Return on equity
-301.4%
Return on assets
-105.1%
ROIC
-317.0%
Interest coverage
-8.9×
Current ratio
1.0×
Free cash flow
-$2M
Tangible book value
$4M
Cash & investments
$4M
Cash runway
10q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| CERRONE GABRIELE M | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-12 | CERRONE GABRIELE M | Grant | 15K | $1.11 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06868628 ↗ | A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) Multiple System Atrophy | PHASE2 | Recruiting | 2027-04-01 |
| NCT06292923 ↗ | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Secondary Progressive Multiple Sclerosis | PHASE2 | Active Not Recruiting | 2026-09-01 |
| NCT06489548 ↗ | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease Dementia, Alzheimers Disease | PHASE2 | Recruiting | 2026-06-01 |
| NCT06890923 ↗ | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis Non-Active Secondary Progressive Multiple Sclerosis | PHASE2 | Recruiting | 2026-04-30 |
| NCT05651269 ↗ | Milciclib in Combination With Gemcitabine in Advanced NSCLC NSCLC | PHASE2 | Unknown | 2024-12-01 |
| NCT05028946 ↗ | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease Crohn's Disease | PHASE1 | Withdrawn | 2023-07-07 |
| NCT05029609 ↗ | Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | PHASE1 | Withdrawn | 2022-11-01 |
| NCT04983446 ↗ | In-patient COVID-19 Study of Intranasal Foralumab Covid19, COVID-19 Lower Respiratory Infection | PHASE2 | Withdrawn | 2022-10-30 |
| NCT06879067 ↗ | Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers Safety, Tolerability | PHASE1 | Completed | 2019-07-23 |
| NCT03109886 ↗ | Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma Hepatocellular Carcinoma | PHASE2 | Completed | 2019-05-16 |
| NCT03291249 ↗ | Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM NASH - Nonalcoholic Steatohepatitis, NAFLD | PHASE2 | Withdrawn | 2018-12-01 |
| NCT01301391 ↗ | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Malignant Thymoma | PHASE2 | Terminated | 2017-05-31 |
| NCT01011439 ↗ | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Thymic Carcinoma | PHASE2 | Terminated | 2017-05-31 |
| NCT06802328 ↗ | Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients Non-Active Secondary Progressive Multiple Sclerosis | — | Available |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-05-01 | 2025-12-31 | 0001213900-26-051015 ↗ |
| 20-F | 2025-05-06 | 2024-12-31 | 0001213900-25-040218 ↗ |
| 20-F | 2024-05-10 | 2023-12-31 | 0001213900-24-041808 ↗ |
| 20-F | 2023-04-26 | 2022-12-31 | 0001213900-23-032763 ↗ |
| 20-F | 2022-05-23 | 2021-12-31 | 0001213900-22-028645 ↗ |
| 20-F | 2021-05-17 | 2020-12-31 | 0001213900-21-027177 ↗ |
| 20-F | 2020-06-17 | 2019-12-31 | 0001213900-20-015211 ↗ |
| 20-F | 2019-04-04 | 2018-12-31 | 0001213900-19-005736 ↗ |